Dre Martina Imbimbo

Cheffe de clinique
Service d'immuno-oncologie
Département d'oncologie UNIL CHUV

Spécialisations

Immuno-oncologie.

Domaines d'intérêt académique et/ou clinique

Tumeurs thoraciques, tumeurs ORL, immunothérapie des tumeurs solides, essais cliniques de phase précoce, thérapie adoptive

Publications scientifiques sélectionnées

2022

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bour

Cancer Discov. 2022 Jan;12(1):108-133

2020

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.

Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V

Cochrane Database Syst Rev. 2020 Dec 14;12:CD013257

2019

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC

Cancer Treat Rev. 2019 May;75:39-51

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

Imbimbo M, Maury JM, Garassino M, Girard N, RARECAREnet Working Group.

Eur J Surg Oncol. 2019 Jan;45(1):75-80

2018

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino

Cancer Treat Rev. 2018 Dec;71:76-87